| 1 |
34210056 | Influence of CYP2C9 Genetic Polymorphisms on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174: A Systematic Review and Meta-Analysis. | 2021 Jun 29 |
3 |
| 2 |
32186616 | [Association between cytochrome p4502c9 polymorphisms and losartan dosing in hypertensive patients]. | 2019 Dec |
2 |
| 3 |
25977991 | Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex. | 2015 Jun |
1 |
| 4 |
24800477 | [Relationship between warfarin dosing and activity of CYP2C9 assessed by the content of losartan and its metabolite E-3174 in the urine of patients with mechanical prosthetic heart valves]. | 2013 |
1 |
| 5 |
21870106 | Repeated administration of berberine inhibits cytochromes P450 in humans. | 2012 Feb |
1 |
| 6 |
22735459 | Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174. | 2012 Sep |
4 |
| 7 |
23093260 | Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes. | 2012 |
2 |
| 8 |
21841812 | Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics. | 2011 Oct |
1 |
| 9 |
19903527 | Development of swelling/floating gastroretentive drug delivery system based on a combination of hydroxyethyl cellulose and sodium carboxymethyl cellulose for Losartan and its clinical relevance in healthy volunteers with CYP2C9 polymorphism. | 2010 Jan 31 |
1 |
| 10 |
20668444 | Clinically significant CYP2C inhibition by noscapine but not by glucosamine. | 2010 Sep |
1 |
| 11 |
19221727 | Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers. | 2009 Jun |
2 |
| 12 |
18445991 | The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan. | 2008 |
1 |
| 13 |
18816302 | Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C > T variation of the drug transporter gene ABCB1 (MDR1). | 2008 Aug |
3 |
| 14 |
15197523 | CYP2C9 genetic variants and losartan oxidation in a Turkish population. | 2004 Jul |
1 |
| 15 |
15289788 | Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. | 2004 Aug |
3 |
| 16 |
12820813 | Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. | 2003 Jun |
2 |
| 17 |
11823761 | Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. | 2002 Jan |
8 |
| 18 |
12235444 | Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. | 2002 Sep |
1 |
| 19 |
11408373 | Role of CYP2C9 polymorphism in losartan oxidation. | 2001 Jul |
1 |
| 20 |
10197301 | The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers. | 1999 Apr |
1 |
| 21 |
9542475 | Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. | 1998 Mar |
2 |
| 22 |
9551703 | Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. | 1998 Feb |
2 |
| 23 |
7736913 | Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. | 1995 Feb |
1 |